Preclinical development of the class I selective histone deacetylase inhibitor OKI-179 for the treatment of solid tumors

2021 ◽  
pp. molcanther.0455.2021
Author(s):  
Jennifer R. Diamond ◽  
Todd M. Pitts ◽  
Dana Ungermannova ◽  
Christopher G Nasveschuk ◽  
Gan Zhang ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Class I ◽  
Preclinical Development ◽  
Deacetylase Inhibitor

scholarly journals A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

2012 ◽  
Vol 18 (9) ◽  
pp. 2687-2694 ◽  
Author(s):  
Udai Banerji ◽  
Leni van Doorn ◽  
Dionysis Papadatos-Pastos ◽  
Rebecca Kristeleit ◽  
Phillip Debnam ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Class I ◽  
Deacetylase Inhibitor ◽  
Pharmacodynamic Study

Abstract B007: OKI-179 is a novel, oral, class I specific histone deacetylase inhibitor in phase 1 clinical trials

2019 ◽  
Author(s):  
Jennifer R Diamond ◽  
Jodi A Kagihara ◽  
Xuedong Liu ◽  
Gilad Gordon ◽  
Amy M Heim ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Phase 1 ◽  
Class I ◽  
Deacetylase Inhibitor

scholarly journals Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0213186 ◽  
Author(s):  
Yuhee Ryu ◽  
Hae Jin Kee ◽  
Simei Sun ◽  
Young Mi Seok ◽  
Sin Young Choi ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Class I ◽  
Deacetylase Inhibitor ◽  
Induced Hypertension
Sign in / Sign up

Export Citation Format

Share Document